Generic Rybelsus Availability
Last updated on Jan 8, 2025.
Rybelsus is a brand name of semaglutide, approved by the FDA in the following formulation(s):
RYBELSUS (semaglutide - tablet;oral)
-
Manufacturer: NOVO
Approval date: September 20, 2019
Strength(s): 3MG [RLD], 7MG [RLD], 14MG [RLD] -
Manufacturer: NOVO
Approval date: December 9, 2024
Strength(s): 1.5MG [RLD], 4MG [RLD], 9MG [RLD]
Has a generic version of Rybelsus been approved?
No. There is currently no therapeutically equivalent version of Rybelsus available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rybelsus. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
Patent 10,086,047
Issued: October 2, 2018
Inventor(s): Sauerberg Per & Bjerregaard Simon & Nielsen Flemming S.
Assignee(s): Novo Nordisk A/SThe present invention relates to solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine.
Patent expiration dates:
- December 16, 2031✓
- December 16, 2031
-
Oral dosing of GLP-1 compounds
Patent 10,278,923
Issued: May 7, 2019
Inventor(s): Nielsen Flemming S. & Sauerberg Per
Assignee(s): Novo Nordisk A/SThe present invention relates to improved uses of GLP-1 peptides in oral therapy.
Patent expiration dates:
- May 2, 2034✓
- May 2, 2034
-
Compositions of GLP-1 peptides and preparation thereof
Patent 10,933,120
Issued: March 2, 2021
Inventor(s): Vilhelmsen Thomas & Eliasen Helle & Hansen Tue
Assignee(s): Novo Nordisk A/SThe invention relates to pharmaceutical compositions comprising a first type of granules and a second type of granules, wherein said first type of granules comprises a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and no GLP-1 peptide, and wherein said second type of granules comprises a GLP-1 peptide and no salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, as well as the intermediate granules, processes for the preparation of the granules and compositions, and use thereof in medicine.
Patent expiration dates:
- March 15, 2033✓
- March 15, 2033
-
Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid
Patent 10,960,052
Issued: March 30, 2021
Inventor(s): Sauerberg Per & Bjerregaard Simon & Nielsen Flemming Seier
Assignee(s): Novo Nordisk A/SThe present invention relates to solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine.
Patent expiration dates:
- December 16, 2031✓
- December 16, 2031
-
Patent 11,382,957
Patent expiration dates:
- December 16, 2031✓
- December 16, 2031
-
Patent 11,759,501
Patent expiration dates:
- March 15, 2033✓
- March 15, 2033
-
Patent 11,759,502
Patent expiration dates:
- March 15, 2033✓
- March 15, 2033
-
Patent 11,759,503
Patent expiration dates:
- March 15, 2033✓
- March 15, 2033
-
Patent 11,833,248
Patent expiration dates:
- February 1, 2039✓✓
- February 1, 2039
-
Acylated GLP-1 compounds
Patent 8,129,343
Issued: March 6, 2012
Inventor(s): Lau Jesper & Bloch Paw & Hansen Thomas Kruse
Assignee(s): Novo Nordisk A/SProtracted GLP-1 compounds and therapeutic uses thereof.
Patent expiration dates:
- December 5, 2031✓✓✓
- December 5, 2031
-
Acylated GLP-1 compounds
Patent 8,536,122
Issued: September 17, 2013
Inventor(s): Lau Jesper & Doerwald Florencio Zaragoza & Bloch Paw & Hansen Thomas Kruse
Assignee(s): Novo Nordisk A/SProtracted GLP-1 compounds and therapeutic uses thereof.
Patent expiration dates:
- March 20, 2026✓✓✓
- March 20, 2026
-
Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
Patent 9,278,123
Issued: March 8, 2016
Inventor(s): Sauerberg Per & Bjerregaard Simon & Nielsen Flemming Seier
Assignee(s): Novo Nordisk A/SThe present invention relates to solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine.
Patent expiration dates:
- December 16, 2031✓✓
- December 16, 2031
More about Rybelsus (semaglutide)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (269)
- Drug images
- Latest FDA alerts (3)
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- FDA approval history
- Drug class: GLP-1 Agonists (Incretin Mimetics)
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.